-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Benzinga·05/21/2026 14:14:55
Listen to the news
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.